A JAK2 mutation is an acquired change in the gene that controls JAK2, a protein your bone marrow relies on to regulate blood cell production. When this gene mutates, it gets stuck in an “always on” position, telling your body to produce too many red blood cells, white blood cells, or platelets. The mutation is found in the vast majority of people diagnosed with a group of blood disorders called myeloproliferative neoplasms (MPNs), which include polycythemia vera, essential thrombocythemia, and myelofibrosis.
How JAK2 Normally Works
JAK2 is a protein that sits on the surface of blood-forming cells in your bone marrow. It acts as a relay switch: when your body needs more blood cells, hormones like erythropoietin (which triggers red blood cell production) and thrombopoietin (which triggers platelet production) dock onto receptors on these cells. JAK2 detects this docking and fires off a chain of signals inside the cell, ultimately reaching the nucleus and switching on the genes responsible for making new blood cells.
Under normal conditions, this signaling shuts off once your body has enough cells. JAK2 activates, does its job, then goes quiet. The system is tightly regulated because overproduction of blood cells can cause serious problems, particularly dangerous blood clotting.
What Goes Wrong With the Mutation
The most common JAK2 mutation is called V617F. At one specific spot on the gene, a single amino acid gets swapped out for another. This small change disrupts the protein’s built-in “off switch,” causing it to send growth signals continuously, even when the body doesn’t need more blood cells. The result is uncontrolled overproduction.
A second, less common type involves changes in a region called exon 12. These mutations also drive excess red blood cell production and are typically found in polycythemia vera patients who test negative for V617F. Both mutation types lead to similar outcomes: a raised red blood cell count, abnormally low levels of erythropoietin (because the body is trying to compensate), and blood cell precursors that grow without their normal hormonal signals.
Which Conditions It Causes
JAK2 mutations are the defining feature of three related blood disorders:
- Polycythemia vera (PV): About 95% of patients carry the V617F mutation. The body makes too many red blood cells, thickening the blood and raising the risk of clots.
- Essential thrombocythemia (ET): Roughly 75% of patients are V617F-positive. The primary problem is excess platelet production, though red and white blood cell counts can also be elevated.
- Primary myelofibrosis (PMF): Around 25% of patients carry the mutation. Scar tissue gradually replaces normal bone marrow, impairing blood cell production over time.
The proportion of mutated cells in your blood, sometimes called the allele burden, appears to influence which condition develops and how severe it is. People with a higher percentage of mutated cells tend to have higher hemoglobin levels, more enlargement of the spleen, and a greater chance of progressing from one MPN to another. The allele burden generally increases from essential thrombocythemia to polycythemia vera to myelofibrosis, suggesting these conditions may exist on a biological spectrum.
Symptoms Linked to JAK2-Driven Disorders
Many people discover their JAK2 mutation through routine blood work before they notice symptoms. When symptoms do appear, they reflect the consequences of having too many blood cells or an overactive bone marrow.
One of the most distinctive symptoms is aquagenic pruritus, an intense itching triggered by contact with water. In a study of 441 polycythemia vera patients, 68% experienced this symptom. It tends to affect the trunk and upper parts of the arms and legs, and most people describe it as itching, though others report stinging, burning, or a tickling sensation. About 15% of those affected rated it as unbearable, and the symptom is linked to lower overall quality of life, higher fatigue, and more pain.
Other common issues include headaches, dizziness, visual disturbances, redness or burning in the hands and feet (called erythromelalgia), night sweats, and unexplained weight loss. Hypertension is notably common, affecting roughly 45% of polycythemia vera patients in the same study. Gout, caused by elevated uric acid from rapid cell turnover, occurs in about 12%.
Blood Clot Risk
The most serious complication of a JAK2 mutation is an increased risk of blood clots, both in arteries and veins. The mutation doesn’t just increase cell numbers. It also makes platelets and white blood cells more “sticky” and active, while pushing the blood plasma into a more clot-prone state. Higher white blood cell counts in particular seem to drive this risk, providing a plausible explanation for why JAK2-positive patients experience more clotting events than those with MPNs driven by other mutations.
Clots can occur in unusual locations, such as the veins draining the liver or the brain’s venous sinuses. In fact, finding a clot in one of these uncommon sites is sometimes what prompts testing for a JAK2 mutation in the first place.
Acquired, Not Inherited
JAK2 mutations are somatic, meaning they arise spontaneously in a single blood-forming stem cell during your lifetime rather than being passed down from a parent. Studies of families with multiple MPN cases have confirmed that even when the mutation runs in a family’s tumor cells, it is not present in the germline DNA passed to children.
That said, genetics still plays a role in susceptibility. First-degree relatives of MPN patients have a five- to seven-fold increased risk of developing an MPN themselves. Research has identified a specific inherited version of the JAK2 gene region (a haplotype) on which the somatic V617F mutation preferentially occurs. This haplotype may account for as much as 50% of the familial risk. So while you can’t inherit the mutation itself, you can inherit a genetic background that makes the mutation more likely to happen.
How JAK2 Mutations Are Detected
Testing for JAK2 mutations is done through a standard blood draw. Two main laboratory methods are used. Quantitative PCR (qPCR) is the more sensitive option, capable of detecting mutant cells when they make up as little as 0.1% of the sample. Next-generation sequencing (NGS) offers a broader look at the genetic landscape and can catch other mutations simultaneously, but its detection threshold is higher, around 2%. In a comparison of 427 patient samples, the two methods agreed almost perfectly when the mutation burden exceeded 2%, but NGS missed 21 samples where qPCR found burdens between 0.1% and 1%.
For most diagnostic purposes, either method is sufficient. NGS is increasingly favored when doctors want to screen for multiple mutations at once, since MPNs can involve changes in other genes as well.
It’s also worth knowing that a JAK2 mutation can exist at very low levels without causing disease. This is called clonal hematopoiesis of indeterminate potential (CHIP), where a mutation is detectable in the blood at a variant allele frequency of 2% or higher but no MPN or other blood disorder is present. CHIP becomes more common with age and is considered a risk factor for eventually developing a blood cancer, though many people with CHIP never do.
Treatment With JAK Inhibitors
The discovery of JAK2’s role in MPNs led to the development of targeted drugs called JAK inhibitors. These medications work by physically blocking the spot on the JAK2 protein where it normally receives its activation energy (the ATP binding site), preventing the constant signaling that drives overproduction.
The primary benefit of JAK inhibitors is symptom relief. They can significantly reduce spleen size, ease fatigue, night sweats, itching, and bone pain, and generally improve quality of life. What they do not do, however, is eliminate the underlying disease. Studies have consistently shown that these drugs provide quality-of-life improvements but have limited ability to change the long-term course of the MPN or substantially reduce the mutant cell burden. For many patients, treatment is about managing the condition as a chronic illness rather than curing it.
Beyond JAK inhibitors, standard management often involves periodic blood draws to keep red blood cell counts in a safe range (particularly for polycythemia vera) and low-dose aspirin to reduce clotting risk. The specific approach depends on which MPN a person has, their age, clotting history, and symptom burden.